Bortezomib: Proteasome Inhibition as a Novel Mechanism of Cancer Therapy-Implications for Hematological Malignancies

Publisher： Bentham Science Publishers

E-ISSN： 1875-628x|4|2|82-86

ISSN： 1570-1808

Source： Letters in Drug Design & Discovery, Vol.4, Iss.2, 2007-03, pp. : 82-86

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Proteasome Inhibition as a New Therapeutic Principle in Hematological Malignancies

By  

Current Drug Targets, Vol. 7, Iss. 10, 2006-10 ,pp. : 1341-1347

Bentham Science Publishers

Access to resources Recommend Favorite

Novel Immunotherapies for Hematological Malignancies

By  

Current Molecular Pharmacology, Vol. 9, Iss. 3, 2016-09 ,pp. : 264-271

Bentham Science Publishers

Access to resources Recommend Favorite

Proteasome Inhibition in Transplantation-Focusing on the Experience with Bortezomib

By  

Current Pharmaceutical Design, Vol. 19, Iss. 18, 2013-06 ,pp. : 3299-3304

Bentham Science Publishers

Access to resources Recommend Favorite

The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib

By  

Current Pharmaceutical Design, Vol. 17, Iss. 15, 2011-05 ,pp. : 1483-1499

Bentham Science Publishers

Access to resources Recommend Favorite

RET inhibition: implications in cancer therapy

By Borrello Maria Grazia   Ardini Elena   Locati Laura D   Greco Angela   Licitra Lisa   Pierotti Marco A  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 4, 2013-04 ,pp. : 403-419

Informa Healthcare

Access to resources Recommend Favorite